SkinBioTherapeutics – positive study results suggest this could be a six bagger from here!
By Tom Winnifrith & Steve Moore | Thursday 3 June 2021
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
SkinBioTherapeutics (SBTX) has announced the results of the AxisBiotix-PsT consumer study of patients suffering from psoriasis and it says that it will now be seeking regulatory approval for the product as a food supplement in parallel in the UK, US and Europe… targeting a commercial launch of theAxisBiotix-Ps™ product in Q4 2021”. Do the maths! This is going to be massive.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.